The pharmacokinetic (PK) characteristics of drugs were altered under high‐altitude hypoxia.
We aim to describe the population PK of atorvastatin (ATV) to identify patient characteristics …

The aim of the present study was to determine whether there is a differing pattern of systemic
exposure to atorvastatin in Asian versus Caucasian subjects by comparison of data obtained …

Upon completion of a one-year multicenter trial, 146 patients with severe
hypercholesterolemia and treated with atorvastatin 80 mg/day were entered into an open …

Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease.
Atorvastatin lowers plasma low-density lipoprotein (LDL) cholesterol levels by inhibition of …

The pharmacodynamic effects and pharmacokinetics of atorvastatin, a potent investigational
inhibitor of HMG‐CoA reductase, were studied in 16 normolipidemic subjects after …

Atorvastatin is a new 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase
inhibitor that reduces plasma cholesterol by inhibiting cholesterol synthesis and increasing …

Background The rate and degree of LDL cholesterol reduction, in the first 2 weeks of
therapy, may relate to the early benefit of hydroxymethyl glutaryl coenzyme A reductase …

Purpose. The effects of morning versus evening administration of atorvastatin in
hyperlipidemic patients were studied. Methods. Patients whose care was managed by a …

To determine whether atorvastatin, a new HMG‐CoA reductase inhibitor, could be
administered with food in Phase II and III clinical trials, a nonblind, randomized, two‐way …

OBJECTIVE: To review the efficacy and safety of atorvastatin in the treatment of
dyslipidemias. DATA SOURCES: A MEDLINE search (January 1960–April 1998), Current …